Clinical trial
A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With…
NCT00190710 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190710 |
|---|---|
| Title | A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer |
| Official title | A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Carboplatin |
| Enrollment | 242 |
| Start date | Mar 1, 2004 |
| Completion | Aug 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 14, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: